Merck (NYSE: MRK) stock rose 2% Friday morning after Deutsche Bank analyst James Shin upgraded the pharmaceutical giant from Hold to Buy, setting a price target of $150.00, up from $115.00.

Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can ...

Shares of Merck & Co. Inc. MRK rose 1.82% to $121.93 Friday, on what proved to be an all-around great trading session for the ...

Merck & Co. Inc. stock reached a 52-week high, closing at $122.69. This milestone highlights a significant upward trend for the pharmaceutical giant, marking a notable recovery and growth over the ...

Merck (MRK) closed the most recent trading day at $106.45, moving +1.13% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.19%. At the same time, the ...

Merck (MRK) closed at $106.45 in the latest trading session, marking a +1.34% move from the prior day. This change outpaced the S&P 500's 0.32% gain on the day. Elsewhere, the Dow saw an upswing of ...

Merck & Co. is no longer a deep-value patent cliff trade but a fairly valued defensive compounder. Read why I have downgraded ...

Merck delivered a strong Q4 double beat, with robust pipeline momentum and a healthy new launch cycle. Read more on the Bullish thesis of MRK stock.

Disclosed in the latest SEC filing, a significant insider purchase on January 28, involves Robert M Davis, Chairman at Merck & Co (NYSE:MRK). What Happened: A Form 4 filing from the U.S. Securities ...